Erasca (ERAS) Interest Coverage Ratio Growth (3y) (2023 - 2026)
Erasca (ERAS) Interest Coverage Ratio Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,734.26 Bn | 65,733.97 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,919.96 Bn | 1,919.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.76 Bn | 465.97 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 69.97 Bn | 61.22 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.72 Bn | 50.53 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 40.09% |
| 10 | Erasca | 5.84 Bn | 5.59 Bn | - | 59.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.58% |
| Dec 31, 2025 | 46.13% |
| Sep 30, 2025 | -70.73% |
| Jun 30, 2025 | -22.77% |
| Mar 31, 2025 | -252.29% |
| Dec 31, 2024 | 41.43% |
| Sep 30, 2024 | -127.40% |
| Jun 30, 2024 | -37.71% |
| Mar 31, 2024 | 58.69% |
| Dec 31, 2023 | 40.64% |
| Sep 30, 2023 | -83.55% |
| Jun 30, 2023 | 87.57% |